POINT Biopharma Global is a radiopharmaceutical company focusing on the clinical development and commercialization of radioligands for cancer treatment. Co.'s product candidates include: PNT2002, which is a prostate-specific membrane antigen (PSMA) targeted radioligand for the treatment of metastatic castration-resistant prostate cancer; PNT2004, which is a fibroblast activation protein-a targeting program being developed for use in several tumor types; PNT2003, which is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors; and PNT2001, which is a PSMA targeting ligand family that utilizes linker technology that promotes increased tumor accumulation. The PNT average annual return since 2020 is shown above.
The Average Annual Return on the PNT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PNT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PNT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|